



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Description Paragraph(s) 68

(51) Int Cl.:
A61K 39/155 ^(2006.01) **C07K 14/135** ^(2006.01)

(86) International application number:
PCT/CN2017/112361

(48) Corrigendum issued on:
25.03.2020 Bulletin 2020/13

(87) International publication number:
WO 2018/095330 (31.05.2018 Gazette 2018/22)

(43) Date of publication:
02.10.2019 Bulletin 2019/40

(21) Application number: **17874887.7**

(22) Date of filing: **22.11.2017**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(72) Inventors:
• **HUANG, Jenmin**
Hsinchu City
Taiwan 300 (CN)
• **HUANG, Limin**
Hsinchu City
Taiwan 300 (CN)

(30) Priority: **22.11.2016 US 201662425078 P**

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(71) Applicant: **National Taiwan University**
Taipei 10617 (TW)

(54) **RECONSTITUTED RSV ANTIGEN**

(57) Provided is an antigen including a recombinant respiratory syncytial virus (RSV) F protein, wherein the recombinant RSV F protein includes an antigenic region flanked with an HRN region and an HRC region, and the antigenic region includes one or more antigenic sites se-

lected from the group consisting of site Ø, site II, and site IV. The present disclosure also provides a nucleic acid molecule encoding the antigen and a vaccine composition including the antigen for eliciting an immune response against RSV




FIG. 1A

Description**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] The present application claims the priority of U.S. Provisional Application Serial No. 62/425,078 filed on November 22, 2016 which is herein incorporated by reference in its entirety.

BACKGROUND**1. Technical Field**

[0002] The present disclosure relates to antigens, nucleic acid molecules, and vaccine compositions for elicitation of an immune response, and more particularly for eliciting an immune response against a respiratory syncytial virus (RSV).

2. Description of Associated Art

[0003] RSV has been recognized as the most common cause of lower respiratory tract infections in infants and young children. According to the report from World Health Organization, RSV is responsible for an estimated 199,000 deaths annually worldwide, and 99% of which occur in developing countries (Nair, H., et al., 2011). RSV can also infect and cause diseases in people of all ages, most severely in the elderly and in immuno-compromised individuals. Most children are infected at least once by age 2 and continue to be re-infected throughout life possibly due to incomplete immunity to RSV (Hall, C.B., et al., 1991).

[0004] Despite the burden of diseases caused by RSV, currently available prophylactic and therapeutic methods in RSV are very limited. For example, a humanized monoclonal antibody, palivizumab (SYNAGIS®; MedImmune, Inc.), comprises 95% human antibody sequence and 5% murine antibody sequences. Palivizumab can treat lower respiratory tract disease caused by RSV by binding to an epitope in the A antigenic site of the F subunit of RSV. However, palivizumab is licensed only for use in high-risk infants. In addition, it has been shown that the antiviral agent, ribavirin, has a therapeutic effect on RSV pneumonia and bronchiolitis, while ribavirin is used to treat RSV infection only in the pediatric population. Furthermore, ribavirin is accompanied by many side effects, e.g., insomnia, dyspnea, headache, nausea, muscle pains, emotional lability, hemolytic anemia, decreased hemoglobin, allergic reactions and liver problems. Moreover, ribavirin is not recommended for pregnant women due to its potential risk to the baby.

[0005] The immune effect of formalin-inactivated RSV (FIRSV) vaccine on infants and young children was evaluated in the late 1960s. Although FIRSV vaccine elicits high levels of antibodies in serum, it failed to prevent or treat the disease caused by RSV. On the contrary, those who had been received FIRSV vaccine during early infancy experienced more serious lower respiratory tract disease upon subsequent re-infection with RSV than unvaccinated individuals. Also, the current study revealed that FIRSV induced prominent alveolitis and perivascularitis in the lungs of RSV challenged mice.

[0006] A number of studies have been conducted for the development of RSV vaccines, including virus like particles (VLPs), subunits, and live-attenuated vaccines. Nevertheless, there is still no licensed vaccine against RSV infections. Due to a tremendous disease burden and limited prophylactic method, the demand for a safe and effective RSV vaccine is now greater than ever.

SUMMARY

[0007] In view of the foregoing, the present disclosure provides an antigen comprising a recombinant respiratory syncytial virus (RSV) F protein to mimic the natural trimeric conformation of the RSV F protein.

[0008] The recombinant RSV F protein comprises an antigenic region flanked with an N-terminal heptad repeat (HRN) region and a C-terminal heptad repeat (HRC) region, wherein the antigenic region comprises one or more antigenic sites selected from the group consisting of site Ø, site II, and site IV, provided that if the antigenic region comprises more than one antigenic sites, then the antigenic sites are linked to each other by a linker, and the linker, on each occurrence, independently consists of 2 to 20 amino acids.

[0009] In an embodiment of the present disclosure, the antigenic region comprises site Ø, site II, and site IV. In another embodiment of the present disclosure, the HRN region is directly linked to site Ø, and the HRC region is linked to site IV by the linker.

[0010] According to a further aspect of the present disclosure, the present disclosure provides a nucleic acid molecule encoding the recombinant RSV F antigen described above.

[0011] According to another aspect of the present disclosure, the present disclosure provides a vaccine composition comprising an effective amount of the antigen or the nucleic acid molecule described above.

[0012] In another embodiment of the present disclosure, the vaccine composition comprising an effective amount of

one or more of the antigens described above and a nucleic acid molecule or a plasmid encoding or expressing the antigen is administered to a subject in need thereof under a condition sufficient to prevent or ameliorate an RSV infection in the subject. The vaccine composition is administered in an amount sufficient to elicit an immune response against an RSV antigen, such as RSV F protein, in the subject.

[0013] The present disclosure provides a recombinant RSV F protein and a nucleic acid molecule encoding the recombinant RSV F protein. Also, the present disclosure provides a vaccine composition comprising an effective amount of the antigen or the nucleic acid molecule. The antigen, nucleic acid molecule and vaccine composition of the present disclosure can induce antibody responses specific for RSV and protect the subject from RSV infection without causing an adverse effect. Further, compared with the wild-type RSV F protein, the recombinant RSV F protein of the present disclosure is shorter in length and can result in a better expression level. As such, the antigen, nucleic acid molecule and vaccine composition of the present disclosure are relatively easy in mass production and more helpful in increasing the specificity of antibody identification and avoiding unnecessary reactions such as allergy.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The present disclosure can be more fully understood by reading the following detailed description of the embodiments, with reference made to the accompanying drawings, wherein:

FIGs. 1A-1C show the schematic diagrams of HR024, HR0, and HR0-30 recombinant proteins, respectively.

FIGs. 2A-2I are results of SDS-PAGE analysis of HR024, HR0, HR0-30 recombinant proteins, and HBc. FIGs. 2A, 2C, 2E, and 2G show Coomassie blue staining of purified HR024, HR0, HR0-30 recombinant proteins, and HBc, respectively; FIGs 2B, 2D, and 2F show Western blotting of purified HR024, HR0, and HR0-30 recombinant proteins using anti-His antibody, respectively; FIG. 2H shows Western blotting of purified HBc using rabbit polyclonal anti-HBc antibody; and FIG. 2I shows Western blotting of purified HBc and HR024 recombinant proteins using mouse monoclonal anti-RSV antibody, respectively.

FIGs. 3A and 3B show the transmission electron microscope (TEM) images of purified HBc and HR024 recombinant proteins, respectively.

FIG. 4 shows the intranasal (IN) immunization schedule. Groups of mice are immunized 3 times with vaccine candidates on week 0, 3, and 6, and received RSV challenge on week 9. A group immunized with formalin-fixed RSV (FIRSV) intramuscularly (i.m) on week 4 before RSV challenge is also included. Mouse serum and bronchoalveolar lavage fluid (BALF) are collected from separate groups with identical dosing regimen 2 days before RSV challenge.

FIGs. 5A-5E show HR024-specific antibody responses in mice received 3 doses of intranasal administration of HR024, HR0, or HR0-30 mixed with or without HBc or CpG. Serum and BALF are collected from the mice 2 days before RSV challenge. FIGs. 5A, 5B, 5C, and 5E show HR024-specific total IgG, IgG1, IgG2a and IgA responses measured from the serum, respectively; and FIG. 5D shows HR024-specific secretory IgA (sIgA) response detected from the BALF.

FIGs. 6A and 6B show mouse body weight changes after RSV challenge. The body weight of naive or vaccinated mice is monitored for 5 days after RSV challenge. Body weight changes are presented as the weight loss percentage compared to day 0.

FIG. 7 shows lung histopathology. Lung tissues are collected from naive or vaccinated mice at day 5 post RSV challenge for histology analysis.

FIG. 8 shows lung virus load. Lung tissues are collected from naive or vaccinated mice at day 5 post challenge for lung virus load analysis by qRT-PCR targeting RSV N gene.

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0015] The following examples are used to exemplify the present disclosure. A person of ordinary skills in the art can conceive the other advantages of the present disclosure, based on the specification of the present disclosure. The present disclosure can also be implemented or applied as described in different examples. It is possible to modify and/or alter the above examples for carrying out this disclosure without contravening its spirit and scope, for different aspects

and applications.

[0016] As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antigen" includes mixtures of antigens; reference to "a pharmaceutically acceptable carrier" includes mixtures of two or more such carriers, and the like. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0017] Furthermore, "and/or" where used herein is to be taken as specific disclosure of the two specified features or components with or without the other. Thus, the term "and/or" used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B," "A (alone)," and "B (alone)."

[0018] The present disclosure provides an antigen comprising a recombinant RSV F protein. The recombinant RSV F protein comprises an antigenic region flanked with an HRN region and an HRC region, and the antigenic region comprises one or more antigenic sites selected from the group consisting of site Ø, site II, and site IV.

[0019] As described herein, RSV has three surface glycoproteins, i.e., small hydrophobic (SH), attachment (G) and fusion (F), encoded by three consecutive genes (SH-G-F). The major target antigens of RSV vaccine development are RSV F and G as these are each capable of generating neutralizing antibodies as well as T cell responses. F is particularly attractive due to its considerable conservation among RSV isolates. Historically, there were two known major antigenic sites found on both the prefusion and postfusion conformations of RSV F associated with neutralizing (NT) activity. They were initially defined by binding to the murine monoclonal antibodies (mAbs) 1129 (site II) (Beeler, J.A. et al., 1989; Arbiza, J., et al., 1992) and 101F (site IV) (Wu, S.J., et al., 2007). Site II is known as the target for palivizumab which can reduce severe RSV disease in high-risk infants. McLellan et al. (McLellan, J.S., et al., 2013) isolated a mouse antibody, 5C4, which neutralized RSV potently but showed no binding to postfusion F protein. 5C4 shares these properties with two other antibodies isolated from immortalized peripheral blood mononuclear cells (PBMCs), D25 and AM22, which have been shown to neutralize RSV with 100 folds greater potency than palivizumab (McLellan, J.S., et al., 2013). D25 and AM22 target site Ø, a metastable antigenic site located on the surface of the prefusion RSV F trimer (Spits, H., et al., 2010; Beaumont, T., et al., 2012). The prefusion and postfusion crystal structures of F protein suggest that while sites II and IV are found on both structures, site Ø appear to be specific for the prefusion form (McLellan, J.S., et al., 2013).

[0020] The fusion peptide region of RSV F is located at the N terminus of the F1 subunit (Collins, P.L., et al., 1996) while the transmembrane segment contains two regions of 4,3-hydrophobic heptad repeats (HR), a sequence motif suggestive of coiled-coil structures (Chambers, P., et al., 1990; Singh, M., et al., 1999). These regions are denoted as HRN and HRC, respectively, and are separated by an intervening domain of about 270 amino acids. HRN and HRC form a trimeric hairpin-like structure, with the HRC regions packing in an antiparallel manner against the inner coiled-coil formed by HRN regions (Baker, K.A., et al., 1999).

[0021] In an embodiment of the present disclosure, the HRN region and the HRC region comprise amino acid sequences at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences of SEQ ID NO: 1 (MAVSKVLHLEGEVNIKIKSALLSTNKAVVSLNNGVSVLT SKVLDLKNYIDKQLL PIVNKQS) and SEQ ID NO: 2 (NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK) and have the same functions as SEQ ID NO: 1 and SEQ ID NO: 2, respectively. In another embodiment of the present disclosure, the antigenic site comprised in the antigenic region may be selected from the group consisting of site Ø, site II, and site IV. The site Ø, site II, and site IV comprise amino acid sequences at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences of SEQ ID NO: 3 (KNYIDKQLLPIVNK), SEQ ID NO: 4 (NSELLSLINDMPITNDQKKLMSN), and SEQ ID NO: 5 (KNRGI-IKTFS) and have the same functions as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively. In another embodiment of the present disclosure, if the antigenic region comprises more than one antigenic sites, then the antigenic sites are linked to each other by a linker, and the linker, on each occurrence, independently consists of 2 to 20 amino acids.

[0022] As used herein, the term "sequence identity" or, for example, comprising a "sequence 80% identical to" refers to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity" may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Included are nucleotides and polypeptides having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity to any of the reference sequences described herein (see, e.g., Sequence Listing), typically where the polypeptide variant maintains at least one biological activity or function of the reference polypeptide.

[0023] In an embodiment of the present disclosure, the antigenic region comprises at least one site Ø directly linked to the HRN region.

[0024] In another embodiment of the present disclosure, the antigenic region comprises one site Ø directly linked to the HRN region and linked to the HRC region by the linker (see, e.g., FIG. 1B). In yet another embodiment, the recombinant RSV F protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical

to the amino acid sequence of SEQ ID NO: 6 (MAVSKVLHLEGEVKNIKSALLSTNKAVVSLNNGVSVLTSTKVLDLKKNYIDKQLL PIVNKQSGSGSGSEFGGSGNFYDPLVFPSEDFDASISQVNEKINQSLAFIRKSEDL LHNVNAGKLEHHHHHH) and has the same function as SEQ ID NO: 6.

[0025] In another embodiment of the present disclosure, the antigenic region comprises four site Ø, and one of which is directly linked to the HRN region (see, e.g., FIG. 1C). In yet another embodiment, the recombinant RSV F protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 7 (MAVSKVLHLEGEVKNIKSALLSTNKAVVSLNNGVSVLTSTKVLDLKKNYIDKQLL PIVNKQSGSGSASSNIKENKCNAAKNYIDKQLLPIVNKGGGSSNIKENKCNAAK NYIDKQLLPIVNKGGGFSNIKENKCNAAKNYIDKQLLPIVNKKLGGSGNFYDPL VFPSEDFDASISQVNEKINQSLAFIRKSEDLHNVNAGKLE) and has the same function as SEQ ID NO: 7.

[0026] In another embodiment of the present disclosure, the antigenic region comprises site Ø, site II, and site IV. In another embodiment of the present disclosure, the HRN region is directly linked to site Ø, and the HRC region is linked to site IV by the linker (see, e.g., FIG. 1A). In yet another embodiment, the recombinant RSV F protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 8 (MAVSKVLHLEGEVKNIKSALLSTNKAVVSLNNGVSVLTSTKVLDLKKNYIDKQLL PIVNKQSGSGSNSELLSLINDMPITNDQKKLMSNNVQIVRQGGGSGCTASNKNRGI IKTFSNGGGSGNFYDPLVFPSEDFDASISQVNEKINQSLAFIRKSEDLHNVNAG K) and has the same function as SEQ ID NO: 8.

[0027] In an embodiment of the present disclosure, the linker, on each occurrence, independently consists of 2 to 20 amino acids, and the linker may independently include, but not limited to, an amino acid sequence of any one of GSGS, GGGG, GGSG, SGSG and GG.

[0028] In an embodiment of the present disclosure, the antigen specifically binds to a 5C4, a D25, or an AM22 prefusion-specific antibody.

[0029] According to a further aspect of the present disclosure, the present disclosure provides a nucleic acid molecule encoding the antigen described above.

[0030] In an embodiment of the present disclosure, the nucleic acid molecule is codon optimized for expression in a prokaryotic cell. In another embodiment, the prokaryotic cell is an *Escherichia coli* cell. In yet another embodiment, the nucleic acid molecule comprises a nucleic acid sequence at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of SEQ ID NO: 9.

[0031] In an embodiment of the present disclosure, the nucleic acid molecule is codon optimized for expression in a eukaryotic cell. In another embodiment, the eukaryotic cell is a yeast cell or a mammalian cell. In yet another embodiment, the mammalian cell is a human cell.

[0032] According to another aspect of the present disclosure, the present disclosure provides a vaccine composition comprising an effective amount of the antigen or the nucleic acid molecule described above.

[0033] In an embodiment, the vaccine composition may be used to induce an immune response to RSV in a subject. Thus, in several embodiments, a therapeutically effective amount of a vaccine composition comprising one or more of the antigens of the present disclosure, or a nucleic acid molecule or a plasmid encoding or expressing the antigen, can be administered to a subject to elicit an immune response to RSV.

[0034] In another embodiment, a therapeutically effective amount of a vaccine composition comprising one or more of the antigens of the present disclosure, or a nucleic acid molecule or a plasmid encoding or expressing the antigen, is administered to a subject in need under conditions sufficient to prevent or ameliorate an RSV infection in the subject. The vaccine composition is administered in an amount sufficient to elicit an immune response against an RSV antigen, such as RSV F protein, in the subject. In an embodiment of the present disclosure, the vaccine composition of the present disclosure may be administered intranasally or intramuscularly to the subject.

[0035] In an embodiment of the present disclosure, the vaccine composition may further comprise a pharmaceutically acceptable carrier and/or an adjuvant.

[0036] As used herein, the "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like which may be appropriate for administration of the vaccine composition of the present disclosure. The pharmaceutically acceptable carrier useful for the present disclosure may include, but not limited to, a preservative, a suspending agent, a tackifier, an isotonicity agent, a buffering agent, and a humectant.

[0037] In another embodiment of the present disclosure, the adjuvant useful for the present disclosure may include, but not limited to, a CpG oligonucleotide and a hepatitis B core virus-like particle (HBc VLP).

[0038] In another embodiment, the vaccine composition administered to the subject comprises a mixture of the antigen and the adjuvant at a weight ratio of 10:1 to 1:10.

[0039] In another embodiment of the present disclosure, the vaccine composition promotes a Th1 immune response.

[0040] Many examples have been used to illustrate the present disclosure. The examples below should not be taken as a limit to the scope of the disclosure.

EXAMPLE**Example 1: Construction of recombinant RSV chimera F protein expression vector**

[0041] Full length cDNA sequence of RSV F protein with optimized codon for *Escherichia coli* (*E. coli*) expression was synthesized (Genomics BioSci & Tech). Using this sequence as the PCR template, four gene fragments of RSV F protein were amplified, including nucleotides 457-633 which contain HRN and site Ø (SEQ ID NO: 10), nucleotides 760-849 which contain site II (SEQ ID NO: 11), nucleotides 1264-1314 which contain site IV (SEQ ID NO: 12), and nucleotides 1426-1560 which contain the C-terminal α -helix (HRC) (SEQ ID NO: 13).

[0042] These four PCR amplicons were linked by overlapping PCR and connected by a glycine-rich linker, such as GSGS, GGGS, GGSG, SGSG and GG, to form a constructed gene (named HRØ24), which was then inserted into the NcoI-XhoI restriction sites of pET28b tagged with 6-His at the C-terminus to obtain an HRØ24 plasmid.

[0043] The process of construction of HRØ, HRØ-3Ø and HBc plasmids were similar to that of the HRØ24 plasmid, except for the differences as follows.

[0044] For the construction of HRØ plasmids, two gene fragments of RSV F protein represented by SEQ ID NOs: 10 and 13 were amplified. These two PCR amplicons were then inserted into the NcoI/BamHI and EcoRI/XhoI restriction sites of pET28a tagged with 6-His at the C-terminus and connected by a glycine-rich linker to obtain an HRØ plasmid.

[0045] For the construction of HRØ-3Ø plasmids, two gene fragments of RSV F protein represented by SEQ ID NOs: 10 and 13 were amplified. Further, three site Ø fragments containing NheI/BamHI, BamHI/EcoRI, or EcoRI/HindIII restriction sites were created by PCR. These five PCR amplicons were then inserted into the NcoI/NheI/BamHI/EcoRI/HindIII/XhoI restriction sites of pET28a tagged with 6-His at the C-terminus and connected by a glycine-rich linker to obtain an HRØ-3Ø plasmid.

[0046] The resulting plasmids were transformed into *E. coli* BL21 (DE3) competent cells for protein expression. The schematic diagrams of HRØ24, HRØ, and HRØ-3Ø recombinant proteins were shown in **FIGs. 1A-1C**, respectively.

Example 2: Construction of HBc VLP expression vector

[0047] Full length cDNA sequence of HBc protein with optimized codon for *Escherichia coli* (*E. coli*) expression was synthesized (Genomics BioSci & Tech). Using this sequence as the PCR template, nucleotides 1-444 of HBc (SEQ ID NO: 14) was amplified and then inserted into the NcoI-XhoI restriction sites of pET28a tagged with 6-His at the C-terminus. The resulting plasmid was transformed into *E. coli* BL21 (DE3) competent cells for protein expression. The primers used for PCR in Examples 1 and 2 were represented by SEQ ID NOs: 15 to 34, shown in Table 1 below.

Table 1. Primer sequences

Primer	Sequence
HRN-NcoI-F	5'- CCG CCA TGG CCG TGT CTA AGG TGC TGC -3' (SEQ ID NO. 15)
HRC-XhoI-R	5'- CAT GCT CGA GCT TGC CGG CGT TCA CAT TG -3' (SEQ ID NO. 16)
HRN-A1-F	5'- CAT CGT GAA CAA GCA GAG CGG TTC TGG TTC TAA CAG CGA GCT GCT GAG -3' (SEQ ID NO. 17)
HRN-A1-R	5'- CTC AGC AGC TCG CTG TTA GAA CCA GAA CCG CTC TGC TTG TTC ACG ATG -3' (SEQ ID NO. 18)
A1-A2-F	5'- GCA GAT CGT GCG GCA GGG TGG TGG TTC TTG CAC CGC CAG CAA C -3' (SEQ ID NO. 19)

EP 3 545 971 A9

(continued)

Primer	Sequence
A1-A2-R	5'- GTT GCT GGC GGT GCA AGA ACC ACC ACC CTG CCG CAC GAT CTG C -3' (SEQ ID NO. 20)
A2-HRC-F	5'- AGA CCT TCA GCA ACG GCG GTG GTT CTG GTA ACT TCT ACG ACC CCC TGG -3' (SEQ ID NO. 21)
A2-HRC-R	5'- CCA GGG GGT CGT AGA AGT TAC CAG AAC CAC CGC CGT TGC TGA AGG TCT -3' (SEQ ID NO. 22)
Site Ø-N-F	5'- GCC GGA TCC AGC AAC ATC AAG GAG AAC AAG TGC AAC GCC GCC AAG AAC TAC ATC GAC AA -3' (SEQ ID NO. 23)
Site Ø-C-R	5'- GCC AAG CTT CTT GTT CAC GAT GGG CAG CAG CTG CTT GTC GAT GTA GTT CTT GGC GGC GTT -3' (SEQ ID NO. 24)
HRN-BamHI-R	5'- GCC GGA TCC AGA ACC AGA ACC GCT CTG CTT G -3' (SEQ ID NO. 25)
HRC-EcoRI-F	5'- CGG AAT TCG GTG GTT CTG GTA ACT TCT ACG AC -3' (SEQ ID NO. 26)
Site Ø-NheI-F	5'- CTA GCT AGC AGC AAC ATC AAG GAG AAC -3' (SEQ ID NO. 27)
Site Ø-BamHI-R	5'- GCC GGA TCC GCC TCC CTT GTT CAC GAT GGG CAG C -3' (SEQ ID NO. 28)
Site Ø-BamHI-F	5'- GCC GGA TCC AGC AAC ATC AAG GAG AAC -3' (SEQ ID NO. 29)
Site Ø-EcoRI-R	5'- CGG AAT TCG CCT CCC TTG TTC ACG ATG GGC AGC -3' (SEQ ID NO. 30)
Site Ø-EcoRI-F	5'- CGG AAT TCA GCA ACA TCA AGG AGA AC -3' (SEQ ID NO. 31)

(continued)

Primer	Sequence
Site Ø-HindIII-R	5'- CCC AAG CTT CTT GTT CAC GAT GGG CAG C -3' (SEQ ID NO. 32)
HBc148-NcoI-F	5'- CCG CCA TGG ACA TTG ACC CTT ATA AAG -3' (SEQ ID NO. 33)
HBc148-XhoI-R	5'- CAT GCT CGA GAA CAG TAG TTT CCG GAA GTG - 3' (SEQ ID NO. 34)

Example 3: Recombinant protein expression and purification

[0048] The recombinant RSV F protein-6-His and HBc-6-His were expressed in the transformed *E. coli* BL21 (DE3) obtained from Examples 1 and 2, and purified using nickel affinity chromatography, respectively. Eluted (with 500 mM imidazole, 50 mM NaH₂PO₄, 300 mM NaCl, pH 8.0) protein was buffer exchanged by gradient dialyzing 1 volume of sample against 200 volumes of dialyzing buffer (from 350 mM, 150 mM to 0 mM imidazole in 1xPBS) for 12h in each step. The dialyzed protein-6-His was concentrated using a centrifugal concentrator (10,000 MWCO, Sartorius) to reach a concentration about 1 mg/mL. Molecule size and purity of the protein were determined by SDS-PAGE.

[0049] A band of identical mobility was detected by immunoblotting using antibodies directed against His tag, and the results were shown in **FIGs. 2B, 2D, and 2F**. A band of identical mobility was detected by immunoblotting using antibodies directed against HBc and RSV, and the results were shown in **FIGs. 2H and 2I**, respectively. Densitometric scanning of Coomassie blue stained gels revealed that the purified proteins HR024, HRØ, HRØ-3Ø and HBc amounted to more than 90% of the total protein (**FIGs. 2A, 2C, 2E, and 2G**), which was sufficiently pure for immunizations.

Example 4: Transmission electron microscope (TEM) images of HR024 and HBc recombinant proteins

[0050] 8 µg of purified HBc VLPs in PBS were adsorbed onto a copper grid (300 mesh) for 3 min at room temperature. Then, the grids were dried gently using filter paper. After staining with 1% uranyl acetate aqueous solution for 30 seconds (s), the excess liquid was removed. The grids were examined with JEM-1400 electron microscope at 80 kV.

[0051] The HBc VLPs have been confirmed to form virus-like particles by TEM (**FIG. 3A**). The TEM image also showed that the recombinant HRØ24 protein formed about 50 nm polymerized nanoparticles (**FIG. 3B**).

Example 5: Animal immunization1. Preparation of RSVA2 strain stock

[0052] RSV A2 strain was obtained from ATCC. Propagation of the virus was performed in HEp-2 cells ATCC. Cells grown in 100 mm Petri dish (Thermo Scientific) up to 80% confluency were inoculated with RSV A2 at an m.o.i. (multiplicity of infection) of 0.2. Virus adsorption was carried out in serum free Dulbecco's Modified Eagle's medium (DMEM) in a CO₂ incubator at 37 °C. After 2 hours, medium was replaced with DMEM supplemented with 2% fetal bovine serum, and the dishes were incubated for another 48 to 72 hours. Supernatants which contain the virus were separated from cell debris by centrifugation at 3,000 rpm for 10 min. Virus was then concentrated by a centrifugal concentrator (100,000 MWCO, Sartorius).

2. RSV plaque assay

[0053] RSV virus titer was determined by plaque assay. Confluent monolayer of HEp-2 cells in 12-well plates were washed with 1xPBS and then infected with RSVA2 virus at various dilutions (10⁻³ to 10⁻⁷). After 2 hours of virus adsorption, supernatant was removed, and the cell monolayer was washed with 1xPBS, followed by overlaying with DMEM+2% fetal bovine serum+0.3% agarose. After 5 days incubation at 37 °C in a CO₂ incubator, cells were fixed with 10% formalin and stained with 0.05% crystal violet for plaque quantification.

3. Vaccine administration and RSV challenge

[0054] Pathogen-free C57BL/6J female mice (6-8 weeks old) were randomly divided into several groups and immunized

by the intranasal (i.n) route with vaccine candidates on day 0, 21, and 42 and challenged with 1×10^6 p.f.u. RSV on day 63 (**FIG. 4**). The vaccine candidates include: 50 μ g HR024; 25 μ g HBc VLPs + 25 μ g HR024; 25 μ g HBc VLPs + 25 μ g HR024 + 20 μ g CpG (TCGTCGTTTTCGGCGCGCGCCG, SEQ ID NO. 37) (Genomics, Taiwan) 25 μ g HBc VLPs + 50 μ g HR024; 25 μ g HBc VLPs + 50 μ g HR024 + 20 μ g CpG; 50 μ g HR0; 25 μ g HBc VLPs + 50 μ g HR0; 25 μ g HBc VLPs + 50 μ g HR0 + 20 μ g CpG; 50 μ g HR0-30; 25 μ g HBc VLPs + 50 μ g HR0-30; and 25 μ g HBc VLPs + 50 μ g HR0-30 + 20 μ g CpG. A naive control group and a group immunized with 25 μ g HBc VLPs intranasally on day 0, 21, and 42 were included. A group immunized with 1×10^5 p.f.u. FIRSV intramuscularly (i.m) on day 35 was also included.

[0055] Before RSV challenge, mouse serum and bronchoalveolar lavage fluid (BALF) were collected from separate groups with identical dosing regimen on day 61. For RSV challenge, the mice were anesthetized with 1.5% isoflurane and then infected by intranasal inoculation of 1×10^6 p.f.u. RSV on day 63. After RSV challenge, body weights of the mice were monitored for 5 days. Finally, the mice were sacrificed on day 68, and the individual lungs were collected for virus load and histopathology experiments.

Example 6: Evaluation of antibody response elicited by vaccine candidates

[0056] Serum and BALF collected from the immunized mice as described in Example 5 were tested for antibody responses by enzyme-linked immunosorbent assay (ELISA). Briefly, a 96-well plate was coated with 50 μ L of purified HR024 (10 μ g/ml) overnight at 4 °C. The plate was blocked with 2% BSA for 1 hour at 37 °C, and incubated with serial dilutions of serum samples (10^{-2} to 5.12×10^{-4}) or BALF (10^{-1} to 1.28×10^{-3}) in assay diluent (1% BSA, 0.05% Tween 20 in 1 $\times$ PBS) for 2 hours at room temperature. Dilution curve was drawn for each sample, and endpoint titers were calculated as the reciprocal of the dilution producing an optical density that was 0.1 U greater than the background value (1/50 dilution of a pooled pre-immune serum or 1/5 dilution of a pooled naive BALF). IgG titers lower than 50 (negative samples) or secretory IgA (sIgA) titers lower than 5 were arbitrarily assigned as 50 or 5.

[0057] Referring to **FIGs. 5A-5E**, it is shown that dosing with HR024, HR0 and HR0-30 can elicit serum HR024-specific total IgG, IgG1, IgG2a, and lung HR024-specific sIgA. Furthermore, by using HBc as an adjuvant, HR024, HR0 and HR0-30 can elicit significant higher serum HR024-specific total IgG, IgG1, IgG2a, IgA and lung HR024-specific sIgA, in which the highest end-point titers were observed in the HBc/HR024 group. Moreover, by using the mixture of HBc and CpG as an adjuvant, HR024 can also elicit higher serum HR024-specific total IgG, IgG1, IgG2a, IgA and lung HR024-specific sIgA.

Example 7: Effects of vaccine candidates on protecting mice against RSV infection

[0058] To evaluate the efficacy when dosing the vaccine candidates 3 times, the immunized mice challenged with live RSV A2 strain as described in Example 5 were used.

1. Mice body weight changes after RSV challenge

[0059] Body weight change of mice following challenge infection is the most important indicator to assess vaccine protective efficacy. Referring to **FIGs. 6A and 6B**, mice immunized with HR024/HBc, HR024/HBc/CpG, HR0-30, HR0-30/HBc, HR0-30/HBc/CpG, HR0/HBc or HR0/HBc/CpG showed less body weight loss compared with the naive group after day 2 post challenge. More specifically, **FIG. 6A** showed about 8-11% body weight loss in the groups of mice received HR024 mixed with HBc. Also, mice immunized with 25 μ g and 50 μ g HR024 mixed with HBc/CpG showed about 16% and 12% body weight loss, respectively, at day 3 post challenge. In addition, **FIG. 6B** demonstrated that mice immunized with HR0/HBc or HR0-30/HBc mixture showed about 12% or 10% body weight loss at day 3 post challenge. In contrast, mice received FIRSV intramuscularly showed the highest body weight loss every day and showed about 25% body weight loss at day 3 post challenge.

[0060] Therefore, the present disclosure provides a better protection to prevent mouse weight loss and an accelerated recovery from initial body weight loss following live RSV challenge. These are evidence that anti-viral immunity elicited by the antigen of the present disclosure confer protection against live RSV A2 strain virus.

2. Lung histopathology after RSV challenge

[0061] For histological analysis, lung samples were fixed in 10% neutral buffered formalin for 24 hrs, embedded in paraffin blocks, sectioned into a thickness of 5 μ m, and stained with hematoxylin and eosin (H&E).

[0062] Referring to **FIG. 7**, lung histopathological changes were observed in the naive group or mice immunized with HBc, HR024, HR0, HR0-30 or FIRSV, wherein FIRSV immunized mice showed a severe level of histopathology. In contrast, mice received HR024/HBc, HR0/HBc or HR0-30/HBc mixture showed none to moderate level of histopathology upon RSV challenge.

3. Lung virus load by quantitative RT-PCR (qRT-PCR)

[0063] Control of lung viral loads is an important parameter in assessing vaccine efficacy since there would be a positive correlation between viral replication and clinical disease during natural or experimental infections (DeVincenzo, J.P., et al., 2005; Karron, R.A., et al., 1997). Therefore, qRT-PCR targeting RSV N gene was performed to quantify mRNA levels in lung tissues.

[0064] Lung extracts were prepared as homogenates using frosted glass slides. Total RNA was prepared by Qiagen RNeasy kit from homogenated samples. Two steps qRT-PCR was performed. The first-strand cDNA was amplified from 2 µg total RNA by SuperScript III Reverse Transcriptase (Invitrogen). The following primer pair was used for qRT-PCR: RSV-A-N-F730: GCAGGATTGTTTATGAATGCC (SEQ ID NO: 35) and RSV-A-N-R857: TCCACAACCTTGTTCCATTTC (SEQ ID NO: 36) for RSV subgroup A viruses. Following optimization, reactions contained: each primer at 200 nM, 1 × Power SYBR Green PCR Master Mix (ABI), 1 µL of cDNA, and water to 10 µL. Real-time PCR was performed using the ABI instrument with the following conditions: 95 for 10 min (1×), 95 for 15 sec, 60 for 60 sec (40x). DNA standards were used to verify the performance of each PCR run and to facilitate the quantification of experimental samples.

[0065] Referring to FIG. 8, lower levels of virus titers were observed in the lungs of mice immunized with HR024, HR024/HBc, HR024/HBc/CpG or FIRSV compared with the naive group. The lung viral titers were significantly lower in the HR024/HBc/CpG or HR024(50)/HBc groups compared to those in the FIRSV group. The results showed that significantly lower viral load was recovered from lungs of animals immunized intranasally with the HR024/HBc mixture and the HR024/HBc/CpG mixture.

[0066] Therefore, these results demonstrated that the antigen of the present disclosure can induce both systemic and mucosal antibody responses specific for RSV. Mice immunized with the antigen of the present disclosure showed protection against RSV without causing lung disease. The antigen of the present disclosure did not over-stimulate lymphocytes compared to FIRSV in a mouse model and offer as a potential safe RSV vaccine candidate.

[0067] Also, the sequence of the antigen of the present disclosure is relatively shorter than the wild type RSV F protein and is therefore relatively easy in mass production. Moreover, the antigen of the present disclosure retains only critical antigenic sites and is therefore more helpful in increasing the specificity of antibody identification and avoiding unnecessary reactions such as allergy than wild-type RSV F proteins.

The present disclosure has been described using exemplary embodiments in detail in the above. However, it is to be understood that the scope of the disclosure is not limited to the disclosed embodiments. On the contrary, it is intended to cover various modifications and similar rearrangement. The scope of the claims therefore should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements.

[0068]

EP 3 545 971 A9

SEQUENCE LISTING

<110> Limin HUANG
 5 <120> RECOMBINANT RSV ANTIGENS, NUCLEIC ACID MOLECULES ENCODING
 THE ANTIGENS, AND VACCINE COMPOSITIONS COMPRISING THE SAME
 <130> 1294/EP
 <150> US 64/425,078
 10 <151> 2016-11-22
 <160> 37
 <170> PatentIn version 3.5
 15 <210> 1
 <211> 60
 <212> PRT
 <213> respiratory syncytial virus
 20 <400> 1
 Met Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile
 1 5 10 15
 25 Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn
 20 25 30
 Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile
 35 40 45
 30 Asp Lys Gln Leu Leu Pro Ile Val Asn Lys Gln Ser
 50 55 60
 35 <210> 2
 <211> 45
 <212> PRT
 <213> respiratory syncytial virus
 40 <400> 2
 Asn Phe Tyr Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser
 1 5 10 15
 45 Ile Ser Gln Val Asn Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg
 20 25 30
 Lys Ser Asp Glu Leu Leu His Asn Val Asn Ala Gly Lys
 35 40 45
 50 <210> 3
 <211> 14
 <212> PRT
 <213> respiratory syncytial virus
 55

EP 3 545 971 A9

<400> 3

Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn Lys
1 5 10

<210> 4

<211> 23

<212> PRT

<213> respiratory syncytial virus

<400> 4

Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp
1 5 10 15

Gln Lys Lys Leu Met Ser Asn
20

<210> 5

<211> 10

<212> PRT

<213> respiratory syncytial virus

<400> 5

Lys Asn Arg Gly Ile Ile Lys Thr Phe Ser
1 5 10

<210> 6

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> recombinant RSV F protein HRO

<400> 6

Met Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile
1 5 10 15

Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn
20 25 30

Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile
35 40 45

Asp Lys Gln Leu Leu Pro Ile Val Asn Lys Gln Ser Gly Ser Gly Ser
50 55 60

Gly Ser Glu Phe Gly Gly Ser Gly Asn Phe Tyr Asp Pro Leu Val Phe
65 70 75 80

Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn Glu Lys Ile

EP 3 545 971 A9

					85						90				95	
5	Asn	Gln	Ser	Leu	Ala	Phe	Ile	Arg	Lys	Ser	Asp	Glu	Leu	Leu	His	Asn
				100					105					110		
	Val	Asn	Ala	Gly	Lys	Leu	Glu									
				115												
10																
	<210>	7														
	<211>	202														
	<212>	PRT														
	<213>	Artificial Sequence														
15																
	<220>															
	<223>	recombinant RSV F protein HRO-30														
	<400>	7														
20	Met	Ala	Val	Ser	Lys	Val	Leu	His	Leu	Glu	Gly	Glu	Val	Asn	Lys	Ile
	1				5					10					15	
	Lys	Ser	Ala	Leu	Leu	Ser	Thr	Asn	Lys	Ala	Val	Val	Ser	Leu	Ser	Asn
				20					25					30		
25																
	Gly	Val	Ser	Val	Leu	Thr	Ser	Lys	Val	Leu	Asp	Leu	Lys	Asn	Tyr	Ile
				35				40					45			
30	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn	Lys	Gln	Ser	Gly	Ser	Gly	Ser
	50						55					60				
	Ala	Ser	Ser	Asn	Ile	Lys	Glu	Asn	Lys	Cys	Asn	Ala	Ala	Lys	Asn	Tyr
	65				70					75						80
35																
	Ile	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn	Lys	Gly	Gly	Gly	Ser	Ser
					85					90					95	
40	Asn	Ile	Lys	Glu	Asn	Lys	Cys	Asn	Ala	Ala	Lys	Asn	Tyr	Ile	Asp	Lys
				100					105					110		
	Gln	Leu	Leu	Pro	Ile	Val	Asn	Lys	Gly	Gly	Glu	Phe	Ser	Asn	Ile	Lys
				115					120				125			
45																
	Glu	Asn	Lys	Cys	Asn	Ala	Ala	Lys	Asn	Tyr	Ile	Asp	Lys	Gln	Leu	Leu
		130				135						140				
50	Pro	Ile	Val	Asn	Lys	Lys	Leu	Gly	Gly	Ser	Gly	Asn	Phe	Tyr	Asp	Pro
	145					150					155					160
	Leu	Val	Phe	Pro	Ser	Asp	Glu	Phe	Asp	Ala	Ser	Ile	Ser	Gln	Val	Asn
55					165					170					175	

EP 3 545 971 A9

Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu
180 185 190

5 Leu His Asn Val Asn Ala Gly Lys Leu Glu
195 200

10 <210> 8
<211> 164
<212> PRT
<213> Artificial Sequence

15 <220>
<223> recombinant RSV F protein HRO24

<400> 8

20 Met Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile
1 5 10 15

Lys Ser Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn
20 25 30

25 Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile
35 40 45

30 Asp Lys Gln Leu Leu Pro Ile Val Asn Lys Gln Ser Gly Ser Gly Ser
50 55 60

35 Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp
65 70 75 80

Gln Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gly Gly
85 90 95

40 Gly Ser Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile Lys Thr Phe
100 105 110

45 Ser Asn Gly Gly Gly Ser Gly Asn Phe Tyr Asp Pro Leu Val Phe Pro
115 120 125

Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn Glu Lys Ile Asn
130 135 140

50 Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu Leu His Asn Val
145 150 155 160

55 Asn Ala Gly Lys

EP 3 545 971 A9

5 <210> 9
 <211> 492
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> recombinant RSV F protein

 <400> 9
 10 atggccgtgt ctaaggtgct gcacctggag ggagaggtga acaagatcaa gagcgccctg 60
 ctgagcacca ataaggccgt ggtgagcctg agcaatggcg tgagcgtgct gacaagcaag 120
 gtgctggacc tcaagaacta catcgacaag cagctgctgc ccatcgtgaa caagcagagc 180
 15 ggttctggtt ctaacagcga gctgctgagc ctgatcaacg acatgcccat caccaacgac 240
 cagaagaagc tgatgtccaa caacgtgcag atcgtgcggc aggggtggtg ttcttgacc 300
 gccagcaaca agaaccgcgg catcatcaag accttcagca acggcggtgg ttctggtaac 360
 20 ttctacgacc ccctggtgtt ccctagcgac gagttcgatg ccagcatcag ccaggtgaac 420
 gagaagatca accagagcct ggccttcacg aggaagagcg acgagctgct gcacaatgtg 480
 aacgccggca ag 492

 25 <210> 10
 <211> 177
 <212> DNA
 <213> respiratory syncytial virus

 30 <400> 10
 gccgtgtcta aggtgctgca cctggagggg gaggtgaaca agatcaagag cgccctgctg 60
 agcaccaata aggccgtggt gagcctgagc aatggcgtga gcgtgctgac aagcaagggtg 120
 35 ctggacctca agaactacat cgacaagcag ctgctgcccc tcgtgaacaa gcagagc 177

 <210> 11
 <211> 90
 <212> DNA
 40 <213> respiratory syncytial virus

 <400> 11
 aacagcgagc tgctgagcct gatcaacgac atgcccatca ccaacgacca gaagaagctg 60
 45 atgtccaaca acgtgcagat cgtgcggcag 90

 <210> 12
 <211> 51
 <212> DNA
 50 <213> respiratory syncytial virus

 <400> 12
 tgcaccgcca gcaacaagaa ccgcggcatc atcaagacct tcagcaacgg c 51

 55 <210> 13

EP 3 545 971 A9

<211> 135
 <212> DNA
 <213> respiratory syncytial virus

5 <400> 13
 aacttctacg accccctggt gttccctagc gacgagttcg atgccagcat cagccaggtg 60
 aacgagaaga tcaaccagag cctggccttc atcaggaaga gcgacgagct gctgcacaat 120
 gtgaacgccg gcaag 135

10

<210> 14
 <211> 462
 <212> DNA
 <213> Hepatitis B virus

15 <400> 14
 atggacattg acccttataa agaatttgga gctactgtgg agttactctc gtttttgcct 60
 tctgacttct ttccttccgt cagagatctt ctagacaccg cctcagctct gtatcgagaa 120
 20 gccttagagt ctctgagca ttgctcacct caccatactg cactcaggca agccattctc 180
 tgctgggggg aattgatgac tctagctacc tgggtgggta ataatttgga agatccagca 240
 tccagggatc tagtagtcaa ttatgttaat actaacatgg gtttaaagat caggcaacta 300
 25 ttgtgggttc atatatcttg ccttactttt ggaagagaga ctgtacttga atatttggtc 360
 tctttcggag tgtggattcg cactcctcca gcctatagac caccaaatgc ccctatctta 420
 tcaacacttc cggaaactac tgttcaccac caccaccacc ac 462

30

<210> 15
 <211> 27
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> HRN-NcoI-F

40 <220>
 <221> primer_bind
 <222> (1) .. (27)

<400> 15
 ccgccatggc cgtgtctaag gtgctgc 27

45

<210> 16
 <211> 29
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> HRC-XhoI-R

55 <220>
 <221> primer_bind

<222> (1) .. (29)

<400> 16

catgctcgag cttgccggcg ttcacattg

29

<210> 17

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> HRN-A1-F

<220>

<221> primer_bind

<222> (1) .. (48)

<400> 17

catcgtgaac aagcagagcg gttctgggtc taacagcgag ctgctgag

48

<210> 18

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> HRN-A1-R

<220>

<221> primer_bind

<222> (1) .. (48)

<400> 18

ctcagcagct cgctgttaga accagaaccg ctctgcttgt tcacgatg

48

<210> 19

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> A1-A2-F

<220>

<221> primer_bind

<222> (1) .. (43)

<400> 19

gcagatcgtg cggcaggggtg gtggttcttg caccgccagc aac

43

<210> 20

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> A1-A2-R

 <220>
 5 <221> primer_bind
 <222> (1)..(43)

 <400> 20
 gttgctggcg gtgcaagaac caccaccctg ccgcacgac tgc 43
 10
 <210> 21
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> A2-HRC-F

 <220>
 20 <221> primer_bind
 <222> (1)..(48)

 <400> 21
 agaccttcag caacggcggg ggttctggta acttctacga cccctgg 48
 25
 <210> 22
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> A2-HRC-R

 <220>
 35 <221> primer_bind
 <222> (1)..(48)

 <400> 22
 ccagggggtc gtagaagtta ccagaaccac cgccgttgct gaaggtct 48
 40
 <210> 23
 <211> 59
 <212> DNA
 <213> Artificial Sequence
 45
 <220>
 <223> SiteO-N-F

 <220>
 50 <221> primer_bind
 <222> (1)..(59)

 <400> 23
 gccggatcca gcaacatcaa ggagaacaag tgcaacgccg ccaagaacta catcgacaa 59
 55
 <210> 24

<211> 60
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> SiteO-C-R

10 <220>
 <221> primer_bind
 <222> (1) .. (60)

<400> 24
 gccaaagcttc ttgttcacga tgggcagcag ctgcttgctg atgtagttct tggcggcggt 60

15 <210> 25
 <211> 31
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> HRN-BamHI-R

25 <220>
 <221> primer_bind
 <222> (1) .. (31)

<400> 25
 gccggatcca gaaccagaac cgctctgctt g 31

30 <210> 26
 <211> 32
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> HRC-EcoRI-F

40 <220>
 <221> primer_bind
 <222> (1) .. (32)

<400> 26
 cggaattcgg tggttctggt aacttctacg ac 32

45 <210> 27
 <211> 27
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> SiteO-NheI-F

55 <220>
 <221> primer_bind
 <222> (1) .. (27)

	<400> 27	
	ctagctagca gcaacatcaa ggagaac	27
5	<210> 28	
	<211> 34	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> SiteO-BamHI-R	
15	<220>	
	<221> primer_bind	
	<222> (1) .. (34)	
	<400> 28	
	gccggatccg cctcccttgt tcacgatggg cagc	34
20	<210> 29	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
25	<220>	
	<223> SiteO-BamHI-F	
30	<220>	
	<221> primer_bind	
	<222> (1) .. (27)	
	<400> 29	
	gccggatcca gcaacatcaa ggagaac	27
35	<210> 30	
	<211> 33	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> SiteO-EcoRI-R	
45	<220>	
	<221> primer_bind	
	<222> (1) .. (33)	
	<400> 30	
	cggaattcgc ctcccttggt cagcatgggc agc	33
50	<210> 31	
	<211> 26	
	<212> DNA	
	<213> Artificial Sequence	
55	<220>	
	<223> SiteO-EcoRI-F	

<220>
 <221> primer_bind
 <222> (1)..(26)
 5 <400> 31
 cggaattcag caacatcaag gagaac 26

 <210> 32
 <211> 28
 10 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> SiteO-HindIII-R
 15

 <220>
 <221> primer_bind
 <222> (1)..(28)
 20 <400> 32
 cccaagcttc ttgttcacga tgggcagc 28

 <210> 33
 <211> 27
 25 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> HBcl48-NcoI-F
 30

 <220>
 <221> primer_bind
 <222> (1)..(27)
 35 <400> 33
 ccgccatgga cattgaccct tataaag 27

 <210> 34
 <211> 30
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> HBcl48-XhoI-R
 45

 <220>
 <221> primer_bind
 <222> (1)..(30)
 50 <400> 34
 catgctcgag aacagtagtt tccggaagtg 30

 <210> 35
 <211> 21
 55 <212> DNA

5 <213> Artificial Sequence
 <220>
 <223> RSV-A-N-F730

 10 <220>
 <221> primer_bind
 <222> (1) .. (21)

 <400> 35
 gcaggattgt ttatgaatgc c 21

 15 <210> 36
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 20 <223> RSV-A-N-R857

 <220>
 <221> primer_bind
 <222> (1) .. (20)
 25 <400> 36
 tccacaactt gttccatttc 20

 30 <210> 37
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 35 <223> CpG

 <400> 37
 tcgtcgtttt cggcgcgcgc cg 22

 40

Claims

- 45 1. An antigen comprising a recombinant respiratory syncytial virus (RSV) F protein, wherein the recombinant RSV F protein comprises an antigenic region flanked with an N-terminal heptad repeat (HRN) region and a C-terminal heptad repeat (HRC) region, and wherein

 50 - the HRN region and the HRC region comprise amino acid sequences at least 80% identical to amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and have the same functions as SEQ ID NO: 1 and SEQ ID NO: 2, respectively;
 - the antigenic region comprises one or more antigenic sites selected from the group consisting of site Ø, site II, and site IV including amino acid sequences at least 80% identical to amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, and having the same functions as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively; and
 55

when the antigenic region comprises more than one antigenic site, the antigenic sites are linked to each other by a linker independently consisting of 2 to 20 amino acids.

2. The antigen of claim 1, wherein the antigenic region comprises at least one site Ø directly linked to the HRN region.
3. The antigen of claim 2, wherein the antigenic region comprises site II, site IV, and the at least one site Ø.
- 5 4. The antigen of claim 3, wherein the HRN region is directly linked to the site Ø, and the HRC region is linked to the site IV by the linker.
- 10 5. The antigen of claim 4, wherein the recombinant RSV F protein comprises an amino acid sequence at least 80% identical to an amino acid sequence of SEQ ID NO: 8 and has the same function as SEQ ID NO: 8.
- 15 6. The antigen of claim 2, wherein the antigenic region comprises four sites Ø.
7. The antigen of claim 6, wherein the recombinant RSV F protein comprises an amino acid sequence at least 80% identical to an amino acid sequence of SEQ ID NO: 7 and has the same function as SEQ ID NO: 7.
- 15 8. The antigen of claim 1, wherein the linker comprises an amino acid sequence of any one of GSGS, GGGS, GGSG, SGSG and GG.
- 20 9. The antigen of claim 2, wherein the antigen specifically binds to a 5C4, a D25, or an AM22 prefusion-specific antibody.
10. A nucleic acid molecule encoding the antigen of claim 1.
11. The nucleic acid molecule of claim 10, being codon optimized for expression in a prokaryotic cell.
- 25 12. The nucleic acid molecule of claim 11, wherein the prokaryotic cell is an *Escherichia coli* cell.
13. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises a nucleic acid sequence at least 80% identical to a nucleic acid sequence of SEQ ID NO: 9.
- 30 14. The nucleic acid molecule of claim 10, being codon optimized for expression in a eukaryotic cell.
15. The nucleic acid molecule of claim 14, wherein the eukaryotic cell is a yeast cell or a mammalian cell.
- 35 16. The nucleic acid molecule of claim 15, wherein the mammalian cell is a human cell.
17. A vaccine composition comprising an effective amount of the antigen of claim 1.
18. The vaccine composition of claim 17, further comprising a pharmaceutically acceptable carrier and/or an adjuvant.
- 40 19. The vaccine composition of claim 18, wherein the adjuvant is a CpG oligonucleotide or a hepatitis B core virus-like particle.
20. The vaccine composition of claim 19, promoting a Th1 immune response.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A

FIG. 2B

FIG. 2C

FIG. 2D

FIG. 2E

FIG. 2F




FIG. 2G

FIG. 2H

FIG. 2I




FIG. 3A




FIG. 3B

FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN2017/112361

A. CLASSIFICATION OF SUBJECT MATTER

A61K 39/155 (2006.01) i; C07K 14/135 (2006.01) i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 39; C07K 14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

VEN; CNABS; CNKI; PubMed; ISI web of knowledge; Genbank; EBI-EMBL; SEQ ID NO: 1-9, 疫苗, 呼吸道合胞体病毒, F 蛋白, 七肽重复, adjuvant, vaccine, respiratory syncytial virus, RSV, fusion glycoprotein, F protein, HRN, HRC, HR, heptad repeat

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015048149 A1 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 02 April 2015 (02.04.2015), claims 1, 6, 8, 28 and 38-40, description, page 2, paragraphs 2-4, page 3, paragraphs 3 and 4, page 11, paragraph 6, and page 58, table	1-20
X	CN 105073196 A (MEDIMMUNE LLC) 18 November 2015 (18.11.2015), claim 6, description, page 9, table 1, and figure 6	1-20
A	CN 1709912 A (INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES) 21 December 2005 (21.12.2005), entire document	1-20

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search 22 January 2018	Date of mailing of the international search report 13 February 2018
Name and mailing address of the ISA State Intellectual Property Office of the P. R. China No. 6, Xitucheng Road, Jimenqiao Haidian District, Beijing 100088, China Facsimile No. (86-10) 62019451	Authorized officer PAN, Hao Telephone No. (86-10) 53961976

FormPCT/ISA/210(secondsheet)(July2009)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN2017/112361

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CN 102481359 A(GLAXOSMITHKLINE BIOLOG SA et al.) 30 May 2012 (30.05.2012), entire document	1-20
A	CN 102548578 A(ID BIOMEDICAL CORP. QUEBEC et al.) 04 July 2012 (04.07.2012), entire document	1-20
A	CN 102946901 A(UNIVERSITY OF COLORADO) 27 February 2013 (27.02.2013), entire document	1-20
A	CN 104853769 A(GLAXOSMITHKLINE BIOLOGICALS SA) 19 August 2015(19.08.2015), entire document	1-20

Form PCT/ISA /210 (continuation of second sheet) (July 2009)

5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2017/112361

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item item 1.c of the first sheet)

10

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

☐ on paper

15

☒ in electronic form

b. (time)

☒ in the international application as filed

20

☐ together with the international application in electronic form

☐ subsequently to this Authority for the purposes of search

25

2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

30

3. Additional comments:

35

40

45

50

Form PCT/ISA/210 (continuation of first sheet (1)) (July 2009)

55

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 International application No.
 PCT/CN2017/112361

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
WO 2015048149 A1	02 April 2015	CA 2925201 A1	02 April 2015
		WO 2015048149 A9	09 July 2015
		EP 3049107 A1	03 August 2016
		US 2015110825 A1	23 April 2015
		JP 2016533332 A	27 October 2016
CN 105073196 A	18 November 2015	EP 2950886 A4	07 September 2016
		US 2015366960 A1	24 December 2015
		EP 2950886 A1	09 December 2015
		AU 2014212268 A1	20 August 2015
		JP 2016508503 A	22 March 2016
		CA 2900110 A1	07 August 2014
		WO 2014121021 A1	07 August 2014
CN 1709912 A	21 December 2005	CN 100339396 C	26 September 2007
CN 102481359 A	30 May 2012	MA 33449 B1	03 July 2012
		EA 201270063 A1	30 July 2012
		JP 6062245 B2	18 January 2017
		IL 217013 D0	29 February 2012
		PT 2445526 T	16 August 2016
		DOP 2011000389 A	30 April 2012
		JP 2016128457 A	14 July 2016
		EA 023054 B1	29 April 2016
		US 9492531 B2	15 November 2016
		PE 15412012 A1	21 December 2012
		HRP 20160798 T1	12 August 2016
		CN 102481359 B	19 August 2015
		SI 2445526 T1	31 August 2016
		CY 1117673 T1	17 May 2017
		AU 2014203636 B2	20 October 2016

Form PCT/ISA/210 (patent family annex) (July 2009)

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 International application No.
 PCT/CN2017/112361

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
		ES 2583257 T3	20 September 2016
		KR 101696002 B1	13 January 2017
		HU E028085 T2	28 November 2016
		SG 176829 A1	30 January 2012
		JP 2012530504 A	06 December 2012
		EP 2445526 A1	02 May 2012
		DK 2445526 T3	27 June 2016
		US 2012093847 A1	19 April 2012
		CR 20120025 A	28 May 2012
		PL 2445526 T3	31 August 2017
		CA 2766211 A1	29 December 2010
		MX 2012000035 A	28 February 2012
		AU 2014203636 A1	31 July 2014
		SI EP2445526 T1	31 August 2016
		EP 2445526 B1	11 May 2016
		KR 20120097472 A	04 September 2012
		ZA 201109199 B	29 August 2012
		AU 2014203636 C1	09 February 2017
		WO 2010149745 A1	29 December 2010
		CO 6480978 A2	16 July 2012
		AU 2010264688 A1	19 January 2012
CN 102548578 A	04 July 2012	EA 201270062 A1	28 February 2013
		CA 2766205 A1	29 December 2010
		EP 2445527 A2	02 May 2012
		MX 2012000036 A	28 February 2012
		JP 2012530761 A	06 December 2012
		US 2012135028 A1	31 May 2012
		US 8889146 B2	18 November 2014

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 International application No.
 PCT/CN2017/112361

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
CN 102946901 A	27 February 2013	KR 20120093811 A	23 August 2012
		ZA 201109164 B	26 September 2012
		JP 5796011 B2	21 October 2015
		SG 176807 A1	30 January 2012
		AU 2010264686 A1	19 January 2012
		WO 2010149743 A2	29 December 2010
		WO 2010149743 A3	10 March 2011
		IL 217008 D0	29 February 2012
		WO 2011094363 A2	04 August 2011
		WO 2011094357 A3	10 November 2011
		WO 2011094357 A2	04 August 2011
		US 2012009212 A1	12 January 2012
		CA 2825952 A1	04 August 2011
		EP 2528623 A2	05 December 2012
CN 104853769 A	19 August 2015	EP 2528622 A2	05 December 2012
		US 2012014972 A1	19 January 2012
		CA 2825861 A1	04 August 2011
		WO 2011094357 A8	19 April 2012
		CN 102939101 A	20 February 2013
		WO 2011094363 A3	13 October 2011
		EA 201590683 A1	30 November 2015
		JP 2016501196 A	18 January 2016
		WO 2014079842 A1	30 May 2014
		AU 2013349778 A1	28 May 2015
		CA 2890135 A1	30 May 2014
		KR 20150085843 A	24 July 2015
		IL 238520 A	30 June 2015
		US 2015329597 A1	19 November 2015

Form PCT/ISA/210 (patent family annex) (July 2009)

INTERNATIONAL SEARCH REPORT
Information on patent family membersInternational application No.
PCT/CN2017/112361

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
		EP 2922570 A1	30 September 2015
		SG 11201503369R A	29 June 2015
		IL 238520 D0	30 June 2015
		MX 2015006377 A	21 July 2015

Form PCT/ISA /210 (patent family annex) (July 2009)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 62425078 [0001]